Viewing StudyNCT01892345

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 1:46 AM
Last Modification Date: 2024-10-26 @ 11:09 AM
Study NCT ID: NCT01892345
Status: TERMINATED
Last Update Posted: 2019-06-26
First Post: 2013-06-20
Brief Title: A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO PREVENT Study
Sponsor: Alexion Pharmaceuticals Inc
Organization: Alexion Pharmaceuticals Inc
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Neuromyelitis Optica
Neuromyelitis Optica Spectrum Disorder
Keywords:
Name View
NMOSD View
Neuromyelitis Optica View
Neuromyelitis Optica Spectrum Disorder View
Devics disease Transverse Myelitis View
Optic Neuritis View
relapse View
eculizumab View
soliris View
NMO-IgG View
CNS Autoimmune Disorders View
Demyelinating Disorders View
NMO View